| Amarin

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV) event from

Page for Amarin

Submitted by amarin on Fri, 08/12/2022 - 14:06

Read more about Page for Amarin

page 3

Submitted by amarin on Fri, 08/12/2022 - 13:41

Read more about page 3

Presenting page 1

Submitted by amarin on Fri, 08/12/2022 - 13:34

Read more about Presenting page 1

Securities offered to employees pursuant to employee benefit plans

Submitted by amarin on Fri, 08/05/2022 - 21:19

Home

Node

Securities offered to employees pursuant to employee benefit plans

Read more about Securities offered to employees pursuant to employee benefit plans

Science & Health

Submitted by amarin on Fri, 08/05/2022 - 17:27

Read more about Science & Health

Duis autem vel eum iriure dolor hendrerit incta vulputate velit esse molestie consequat

Investors Relations

Submitted by amarin on Fri, 08/05/2022 - 17:25

Read more about Investors Relations

Lorem ipsum dolor sit amet consetetur sadipscing elitr etidat sed diam nonumy eirmod tempor invidunt ut labore.

Subscribe to